Novo Nordisk A/S (NOVOb.CO)
Fri, Jun 8 2018
COPENHAGEN Shares in Novo Nordisk opened down 4 percent on Friday after a media report citing anonymous sources said the world's biggest diabetes drug company mulls axing up to 3,000 staff and dropping its long-term financial targets.
COPENHAGEN, June 7 Novo Nordisk is considering laying-off up to 3,000 staff and dropping its long-term financial targets due to challenging market conditions in the United States, Danish daily Borsen reported Thursday citing unnamed sources.
LONDON/COPENHAGEN Novo Nordisk said data from a large final-stage study of a pill it hopes will transform the diabetes market proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim's established Jardiance.
LONDON, May 29 An experimental diabetes pill from Novo Nordisk proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim's established Jardiance in a clinical study, the Danish drugmaker said on Tuesday.
* AS PART OF UPTO DKK 14 BILLION 2018 SHARE REPURCHASE PROGRAMME, CO INITIATED NEW SHARE REPURCHASE PROGRAMME FOR AN AMOUNT OF UP TO DKK 2.7 BILLION
BRIEF-Novo Nordisk A/S purchases B Shares worth Dkk 1,038 Mln from Novo Holdings A/S under 2018 share repurchase programme
* NOVO NORDISK A/S PURCHASES B SHARES WORTH DKK 1,038 MILLION FROM NOVO HOLDINGS A/S UNDER THE 2018 SHARE REPURCHASE PROGRAMME
May 2 NOVO NORDISK A/S CEO LARS FRUERGAARD JORGENSEN SAID AT CALL AFTER Q1 EARNINGS:
* Positive feedback on new Ozempic drug (Adds detail, guidance in Danish crowns)
COPENHAGEN, May 2 Denmark's Novo Nordisk , the world's biggest maker of diabetes drugs, posted a posted first-quarter operating profit above expectations on Wednesday and lifted the lower end of its 2018 sales and profit outlook.
* OPERATING PROFIT DECREASED BY 8% IN DANISH KRONER AND INCREASED BY 6% IN LOCAL CURRENCIES IN THE FIRST THREE MONTHS OF 2018